Changes in intestinal microbiota in HIV-1-infected subjects following cART initiation: Influence of CD4+ T cell count article

Emerging Microbes and Infections

Volumn 7, Issue 1, 2018, Pages

  Ji, Yongjia ^a   Zhang, Fengdi ^a   Zhang, Renfang ^a   Shen, Yinzhong ^a   Liu, Li ^a   Wang, Jiangrong ^a   Yang, Junyang ^a   Tang, Qi ^a   Xun, Jingna ^a   Qi, Tangkai ^a   Wang, Zhenyan ^a   Song, Wei ^a   Tang, Yang ^a   Chen, Jun ^a   Lu, Hongzhou ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 9; LIPOPOLYSACCHARIDE BINDING PROTEIN; MACROPHAGE DERIVED CHEMOKINE; RNA 16S; BIOLOGICAL MARKER;

ADULT; ANALYTIC METHOD; ANTIRETROVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMBINED ANTIRETROVIRAL THERAPY; DYSBIOSIS; FECES MICROFLORA; FEMALE; FOLLOW UP; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTESTINE FLORA; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIMPSON INDEX; SPECIES TRANSLOCATION; VIRUS LOAD; BIODIVERSITY; BIOLOGY; CD4 CD8 RATIO; DRUG EFFECT; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METAGENOME; METAGENOMICS; PROCEDURES; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIODIVERSITY; BIOMARKERS; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; COMPUTATIONAL BIOLOGY; FEMALE; GASTROINTESTINAL MICROBIOME; HIV INFECTIONS; HIV-1; HUMANS; MALE; METAGENOME; METAGENOMICS; RNA, RIBOSOMAL, 16S; VIRAL LOAD;

EID: 85048948019     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/s41426-018-0117-y     Document Type: Article

References (38)

1. Gill, S. R. et al. Metagenomic analysis of the human distal gut microbiome. Science 312, 1355-1359 (2006).
2. Round, J. L. &Mazmanian, S. K. The gut microbiome shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 9, 313-323 (2009).
3. Dragic, T., Litwin, V. &Allaway, G. P. HIV-1 entry into CD4 plus cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 667 (1996).
4. Sandler, N. G. &Douek, D. C. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat. Rev. Microbiol. 10, 655-666 (2012).
5. Brenchley, J. M. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365-1371 (2006).
6. Zevin A. S., McKinnon L., Burgener A., Klatt N. R. Microbial translocation and microbiome dysbiosis in HIV-associated immune activation. Curr. Opin. HIV. AIDS. 11, 182-190 (2016).
7. Sun, Y. et al. Fecal bacterial microbiome diversity in chronic HIV-infected patients in China. Emerg. Microbes Infect. 5, e31 (2016).
8. Nowak, P. et al. Gut microbiota diversity predicts immune status in HIV-1 infection. AIDS 29, 2409-2418 (2015).
9. Chen, J. et al. Anti-retroviral therapy decreases but does not normalize indoleamine 2,3-dioxygenase activity in hiv-infected patients. Plos ONE 9, e100446 (2014).
10. Paiardini, M. &Muller-Trutwin, M. HIV-associated chronic immune activation. Immunol. Rev. 254, 78-101 (2013).
11. Nix, L. M. &Tien, P. C.Metabolic syndrome, diabetes, and cardiovascular risk in HIV. Curr. HIV/AIDS Rep. 11, 271-278 (2014).
12. Aron-Wisnewsky, J. &Clement, K. The gut microbiome, diet, and links to cardiometabolic and chronic disorders. Nat. Rev. Nephrol. 12, 169-181 (2016).
13. Wu, G. D. et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 334, 105-108 (2011).
14. Noguera-Julian, M. et al. Gut microbiota linked to sexual preference and HIV infection. EBioMedicine 5, 135-146 (2016).
15. Li, S. X. et al. Complexities of gut microbiome dysbiosis in the context of HIV infection and antiretroviral therapy. Clin. Pharmacol. Ther. 99, 600-611 (2016).
16. Dillon, S. M., Frank, D. N. &Wilson, C. C. The gut microbiome and HIV-1 pathogenesis: a two way street. AIDS 30, 2737-2751 (2016).
17. Tincati, C., Douek, D. C. &Marchetti, G. Gut barrier structure,mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection. AIDS Res Ther. 13, 19 (2016).
18. Dubourg, G., Surenaud, M., Lévy, Y., Hüe, S. &Raoult, D. Microbiome of HIVinfected people. Microb. Pathog. 106, 85-93 (2017).
19. Dillon, S. et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol. 7, 983 (2014).
20. McHardy, I. H. et al. HIV infection is associated with compositional and functional shifts in the rectal mucosal microbiota. Microbiome 1, 26 (2013).
21. Mutlu, E. A. et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. Plos Pathog. 10, e1003829 (2014).
22. Vujkovic-Cvijin, I. et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci. Transl. Med. 5, 193ra91-ra91 (2013).
23. Lozupone, C. A. et al. Alterations in the gut microbiota associated with HIV-1 infection. Cell Host Microbe 14, 329-339 (2013).
24. Dubourg, G. Impact of HIV on the human gut microbiota: challenges and perspectives. Human Micro. J. 2, 3-9 (2016).
25. Bäckhed, F. Programming of host metabolism by the gut microbiota. Ann. Nutr. Metab. 58(Suppl. 2), 44-52 (2011).
26. Scher, J. U. et al. Decreased bacterial diversity characterizes an altered gut microbiota in psoriatic arthritis and resembles dysbiosis of inflammatory bowel disease. Arthritis Rheumatol. (Hoboken, NJ) 67, 128-139 (2015).
27. Jenabian, M. A. et al. Immunosuppressive tryptophan catabolism and gut mucosal dysfunction following early HIV infection. J. Infect. Dis. 212, 355-366 (2015).
28. Sherry, B. T.-O. P. et al. Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein 1 beta. J. Exp. Med. 168, 2251-2259 (1988).
29. Mantovani, A., Gray, P. A., Van Damme, J. &Sozzani, S. Macrophage-derived chemokine (MDC). J. Leukoc. Biol. 68, 400-404 (2000).
30. Gaidt, M. M. &Hornung, V. Alternative inflammasome activation enables IL-1beta release from living cells. Curr. Opin. Immunol. 44, 7-13 (2017).
31. Zittermann, S. I. &Issekutz, A. C. Basic fibroblast growth factor (bFGF, FGF-2) potentiates leukocyte recruitment to inflammation by enhancing endothelial adhesion molecule expression. Am. J. Pathol. 168, 835-846 (2006).
32. Kasza, A. IL-1 and EGF regulate expression of genes important in inflammation and cancer. Cytokine 62, 22-33 (2013).
33. Alam, R. Chemokines in allergic inflammation. J. Allergy Clin. Immunol. 99, 273-277 (1997).
34. Hamilton, J. A. Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 8, 533-545 (2008).
35. Shilaih, M. et al. Antibacterial effects of antiretrovirals, potential implications for microbiome studies in HIV. Antivir. Ther. 23, 91-94 (2017).
36. Ahmad, A. et al. Combination antiretroviral therapy and indoleamine 2,3-dioxygenase in HIV infections: challenges and new opportunities. AIDS 30, 1839-1841 (2016).
37. Villanueva-Millan, M. J., Perez-Matute, P., Recio-Fernandez, E., Lezana Rosales, J. M. &Oteo, J. A. Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients. J. Int AIDS Soc. 20, 1-13 (2017).
38. Tyler, A. D., Smith,M. I. &Silverberg, M. S. Analyzing the humanmicrobiome: a "how to" guide for physicians. Am. J. Gastroenterol. 109, 983-993 (2014).